Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction (Q40783270)

23 September 2017

1 reference

title

Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction (English)

1 reference

23 September 2017

8

Gilles Montalescot

1 reference

23 September 2017

Stefano Savonitto

1

1 reference

23 September 2017

Giuseppe De Luca

2

1 reference

23 September 2017

Patrick Goldstein

3

1 reference

23 September 2017

Arnoud van T' Hof

4

1 reference

23 September 2017

Uwe Zeymer

5

1 reference

23 September 2017

Nuccia Morici

6

1 reference

23 September 2017

Holger Thiele

7

1 reference

23 September 2017

Leonardo Bolognese

9

1 reference

23 September 2017

29 June 2015

1 reference

European heart journal. Acute cardiovascular care

23 September 2017

18

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

23 September 2017

6

1 reference

23 September 2017

2

1 reference

23 September 2017

173-190

1 reference

Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?

23 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribu

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Composition of coronary thrombus in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Prognostic significance and magnetic resonance imaging findings in aborted myocardial infarction after primary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Bivalirudin during primary PCI in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Prehospital ticagrelor in ST-segment elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Time to treatment and three-year mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction-a DANish Trial in Acute Myocardial Infarction-2 (DANAMI-2) substudy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Time-to-treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Time-to-treatment and infarct size in STEMI patients undergoing primary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Impact of delay to reperfusion on reperfusion success, infarct size, and clinical outcomes in patients with ST-segment elevation myocardial infarction: the INFUSE-AMI Trial (INFUSE-Anterior Myocardial Infarction).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Enhancing the efficacy of delivering reperfusion therapy: a European and North American experience with ST-segment elevation myocardial infarction networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Five-year survival in patients with ST-segment-elevation myocardial infarction according to modalities of reperfusion therapy: the French Registry on Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) 2005 Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab -- EUROTRANSFER Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

A comparison between upfront high-dose tirofiban versus provisional use in the real-world of non-selected STEMI patients undergoing primary PCI: Insights from the Zwolle acute myocardial infarction registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Facilitated PCI in patients with ST-elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Benefit of Facilitated Percutaneous Coronary Intervention in High-Risk ST-Segment Elevation Myocardial Infarction Patients Presenting to Nonpercutaneous Coronary Intervention Hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

1-Year Survival in a Randomized Trial of Facilitated Reperfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb-IIIa facilitated primary angioplasty (from the EGYPT cooperation).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Impact of early tirofiban administration on myocardial salvage in patients with acute myocardial infarction undergoing infarct-related artery stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Prehospital high-dose tirofiban in patients undergoing primary percutaneous intervention. The AGIR-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Impact of early abciximab administration on infarct size in patients with ST-elevation myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Prehospital Abciximab in ST-Segment Elevation Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Early abciximab administration in acute myocardial infarction treated with primary coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Impact of early abciximab administration on myocardial reperfusion in patients with ST-segment elevation myocardial infarction pretreated with 600 mg of clopidogrel before percutaneous coronary intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Effect of Early Treatment With Tirofiban on Initial TIMI Grade 3 Flow of Patients With ST Elevation Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Abciximab as Adjunctive Therapy to Reperfusion in Acute ST-Segment Elevation Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Intravenous platelet blockade with cangrelor during PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Platelet inhibition with cangrelor in patients undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Effect of platelet inhibition with cangrelor during PCI on ischemic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Bivalirudin started during emergency transport for primary PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Acute Stent Thrombosis After Primary Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Rivaroxaban in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Clopidogrel with or without omeprazole in coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Gro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Stent thrombosis: a clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Long-term use of ticagrelor in patients with prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Randomized Comparison of Pre-Hospital–Initiated Facilitated Percutaneous Coronary Intervention Versus Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction Very Early After Symptom Onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Time-dependency, predictors and clinical impact of infarct transmurality assessed by magnetic resonance imaging in patients with ST-elevation myocardial infarction reperfused by primary coronary percutaneous intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Optimisation of therapeutic strategies for ST-segment elevation acute myocardial infarction: the impact of a territorial network on reperfusion therapy and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Morphine Is Associated With a Delayed Activity of Oral Antiplatelet Agents in Patients With ST-Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

Implementation of Guidelines Improves the Standard of Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F2048872615590148

21 January 2018

Identifiers

DOI

10.1177/2048872615590148

1 reference

23 September 2017

1 reference